Report: U.S. economic burden of chronic diseases tops $3.8 trillion—and expected to double

According to a report from Fitch Solutions, aggregate annual costs of the leading chronic medical conditions are approximately $1.1 trillion due to expenses from hospital care, physician visits, pharmaceuticals, medical devices and home care. (Getty/ Ocskaymark)

The U.S. economic burden of chronic diseases such as Alzheimer's, diabetes, heart disease, obesity and cancer has reached about $3.8 trillion in direct and indirect costs—or nearly one-fifth of GDP, according to a new report from Fitch Solutions, which is a unit of Fitch Group.

And as the baby boomer population ages alongside a concurrent increase in the prevalence of noncommunicable diseases, that figure is expected to double within the next 30 years, Fitch reports.

"This considerable financial burden is ultimately borne by society as a whole, but the individuals affected by these chronic diseases will be disproportionately impacted," the report said.

Conference

2019 Drug Pricing and Reimbursement Stakeholder Summit

Given federal and state pricing requirements arising, press releases from industry leading pharma companies, and the new Drug Transparency Act, it is important to stay ahead of news headlines and anticipated requirements in order to hit company profit targets, maintain value to patients and promote strong, multi-beneficial relationships with manufacturers, providers, payers, and all other stakeholders within the pricing landscape. This conference will provide a platform to encourage a dialogue among such stakeholders in the pricing and reimbursement space so that they can receive a current state of the union regarding regulatory changes while providing actionable insights in anticipation of the future.

RELATED: Chronic conditions a major driver of healthcare spending

According to the report, aggregate annual costs of the leading chronic medical conditions are approximately $1.1 trillion due to expenses from hospital care, physician visits, pharmaceuticals, medical devices and home care.  

But indirect costs, such as diminished productivity, early retirement and premature mortality, are about $3.7 trillion.

Among the disease-specific findings, the report pointed out the total cost of diabetes diagnoses jumped to $327 billion in 2017 from $245 billion in 2012. Meanwhile, direct costs for heart disease reached $318 billion in 2017. Total arthritis-attributable medical expenditure and earnings losses in 2013 reached $304 billion, the report said.   

Alzheimer’s disease and other forms of dementia in the U.S. are estimated to cost $290 billion in 2019, and estimated direct medical costs for cancer were $80 billion in 2015.

Suggested Articles

Health insurers’ financial performance is on a continuing upward trend, but political and legal risks could pose a threat to that growth.

Senate lawmakers released a draft package of legislation Thursday aimed at curbing health care costs they said they believe they can pass on a bipartisan basis…

Attorneys general seeking to defend the ACA argue that their opponents—including the DOJ—have poor legal standing to challenge the law.